WebDoctor Encyclopedia

Article

ABVD Chemotherapy

What is ABVD chemotherapy?

ABVD is a combination of four chemotherapy drugs used to treat Hodgkin lymphoma. The name comes from the first letters of the drugs:

Letter Drug Drug family
A Adriamycin (doxorubicin) Anthracycline
B Bleomycin Anti-tumour antibiotic
V Vinblastine Vinca alkaloid
D Dacarbazine Alkylating-type agent

All four drugs are given by drip or injection into a vein on the same day. Treatment is repeated every 2 weeks, and two treatment days make up one 28-day cycle. Most people have between 2 and 6 cycles, depending on the stage of the lymphoma and how it responds.

ABVD is one of the most widely used regimens for Hodgkin lymphoma in the world. It cures most people with early-stage disease and many with advanced disease. It is usually given as an outpatient treatment, so you can go home on the same day.

A brief history

In the 1960s, the MOPP regimen became the first chemotherapy combination to cure advanced Hodgkin lymphoma, but it caused infertility and a raised risk of leukaemia in many patients. In the 1970s, Gianni Bonadonna and colleagues in Milan developed ABVD as an alternative. In 1992, a large American trial showed that ABVD was at least as effective as MOPP-based treatment and gentler on the bone marrow (Canellos et al., 1992). ABVD then became the standard first treatment in many countries.

1. Key facts at a glance

Feature Details
Type of treatment Combination chemotherapy
Main use Hodgkin lymphoma
How it is given Drips and injections into a vein
Schedule Days 1 and 15 of each 28-day cycle
Number of cycles Usually 2-6
Time per treatment day About 2-4 hours
Main side effects Nausea, tiredness, hair loss, infection risk, lung damage from bleomycin, heart effects from doxorubicin

2. How it works

How each drug acts

Drug How it damages cancer cells
Doxorubicin Slips between DNA strands and blocks an enzyme needed to copy DNA
Bleomycin Breaks DNA strands
Vinblastine Stops cells from dividing by blocking the internal structures that pull chromosomes apart
Dacarbazine Adds chemical groups to DNA so it cannot be copied properly

Each drug attacks cancer cells in a different way. Using them together increases the chance of killing all the lymphoma cells and lowers the chance that the cancer becomes resistant.

Why Hodgkin lymphoma responds well

Hodgkin lymphoma is one of the most chemotherapy-sensitive cancers. Its characteristic cells, called Reed-Sternberg cells, are surrounded by large numbers of normal immune cells. When chemotherapy kills the cancer cells, the lymph nodes often shrink quickly.

Why the schedule is every 2 weeks

The 2-week gap gives the bone marrow and other healthy tissues time to recover between treatments. Keeping to the schedule matters, because delays or dose cuts may make treatment less effective. With ABVD, many centres continue treatment on time even if the white cell count is somewhat low on the day, as long as you are well, because studies have suggested this is generally safe. Your team will decide what is right for you.

3. Who it is for

Conditions treated

Condition Role of ABVD
Hodgkin lymphoma Standard first treatment for many adults with early-stage and advanced classical Hodgkin lymphoma

How treatment depends on stage

Stage group Typical approach
Early, favourable 2-3 cycles of ABVD, sometimes followed by radiotherapy
Early, unfavourable 4 cycles of ABVD, sometimes followed by radiotherapy
Advanced Up to 6 cycles, guided by PET scans

PET-guided treatment

A PET-CT scan after the first 2 cycles shows how well the lymphoma is responding. If the scan is clear, treatment may be shortened, radiotherapy may be avoided, or bleomycin may be dropped. If the scan still shows active lymphoma, treatment may be intensified.

Who may need a different regimen

Some younger people with advanced or high-risk disease are offered more intensive chemotherapy, such as escalated BEACOPP. Older people may not tolerate bleomycin well and may receive modified treatment. Nodular lymphocyte-predominant Hodgkin lymphoma, a rarer type, is often treated differently.

4. Before treatment

Step Why it is done
PET-CT scan Shows the stage of the lymphoma
Blood tests Blood counts, kidney and liver function
Heart scan Doxorubicin can affect the heart
Lung function tests Bleomycin can affect the lungs
Fertility discussion Sperm banking or egg storage may be offered
Hepatitis and HIV tests Infections may need treatment or monitoring
Central line or port Some drugs irritate veins; a line may be placed

Smoking

Bleomycin can damage the lungs, and smoking increases this risk. Stopping smoking before and during treatment is strongly advised. Your team can refer you to a support service.

5. What to expect: step by step

Step What happens
1. Blood test Usually a day or two before each treatment
2. Review A nurse or doctor checks for side effects
3. Anti-sickness medicines Given before chemotherapy
4. Doxorubicin Given as an injection or short drip; it is red
5. Bleomycin and vinblastine Given as injections or drips
6. Dacarbazine Given as a drip over about 30-60 minutes
7. Go home With anti-sickness tablets
8. Repeat Two weeks later

Your urine may turn red

Doxorubicin is red and can colour your urine pink or red for a day or two. This is harmless and expected.

Vein discomfort

Dacarbazine can cause a burning or aching feeling along the vein during the drip. Slowing the drip or applying a warm pack often helps. Tell the nurse at once if you feel pain, stinging or swelling at the needle site, because doxorubicin can damage tissue if it leaks out of the vein.

A typical week after treatment

Many people feel tired and slightly sick for 2-3 days after each treatment day, and then gradually pick up. The second week of each fortnight is often the best time for social plans or work. Side effects tend to build up over the course, so the later cycles can feel harder than the first ones. Keeping a simple diary of symptoms can help you and your team see patterns and adjust anti-sickness or other medicines.

6. Side effects and risks

Common side effects

Side effect What to expect
Nausea and vomiting Common, especially on treatment days; usually well controlled
Tiredness Builds up over the course
Hair loss Common; hair grows back after treatment
Infection risk White cell counts fall; fever needs urgent attention
Sore mouth Mouth ulcers can occur
Constipation Vinblastine can slow the bowel
Tingling or numbness From vinblastine; usually mild
Skin darkening Bleomycin can darken skin and nails
Fever after bleomycin Short-lived fever or chills on the day of treatment

Serious risks

Risk Notes
Bleomycin lung toxicity Inflammation or scarring of the lungs; report new cough or breathlessness
Heart damage Doxorubicin can weaken the heart muscle, especially at high total doses
Neutropenic fever Infection with low white cells is an emergency
Second cancers Small long-term risk, lower than with older regimens

Fertility

ABVD is less likely to cause infertility than many other lymphoma treatments, and most people’s fertility recovers. Even so, fertility preservation is usually discussed before starting. Effective contraception is needed during treatment, because chemotherapy can harm an unborn baby.

7. Results and outlook

Study Main finding
CALGB trial, advanced Hodgkin lymphoma ABVD was as effective as MOPP alternating with ABVD and better than MOPP alone, with less effect on the bone marrow; five-year failure-free survival was 61% with ABVD versus 50% with MOPP (Canellos et al., 1992)
RAPID trial, early-stage disease After 3 cycles of ABVD and a clear PET scan, 3-year progression-free survival was about 95% with radiotherapy and 91% without it (Radford et al., 2015)
RATHL trial, advanced disease When the PET scan was clear after 2 cycles, leaving out bleomycin for the remaining cycles gave similar results and fewer lung problems (Johnson et al., 2016)
ECHELON-1 trial, advanced disease Replacing bleomycin with brentuximab vedotin modestly improved disease control but caused more nerve damage (Connors et al., 2018)

Outlook

Most people with Hodgkin lymphoma are cured. In the RATHL trial, overall survival at 3 years was about 97% among those with a clear interim scan (Johnson et al., 2016). Results depend on stage, age, general health and how the lymphoma responds.

Dropping bleomycin

Bleomycin is the drug most likely to cause lung problems. Since the RATHL trial, many people whose PET scan is clear after 2 cycles continue with AVD alone, which keeps the benefits while lowering lung risks.

8. Recovery and aftercare

During treatment

Tip Why
Check your temperature if unwell Fever can signal infection
Keep the emergency number to hand For fever, breathlessness or bleeding
Eat small, frequent meals Helps with nausea
Look after your mouth Soft toothbrush and mouthwashes
Prevent constipation Fluids, fibre and laxatives if needed
Avoid smoking Protects the lungs
Avoid live vaccines Unless your team agrees

After treatment

A PET-CT scan at the end of treatment checks whether the lymphoma has gone. You then have regular follow-up appointments, often for several years.

Late effects

Late effect What to watch for
Heart problems Breathlessness, swelling or palpitations
Lung problems Persistent cough or breathlessness
Second cancers Attend screening programmes
Fatigue Can last months after treatment

Long-term follow-up clinics help survivors manage late effects. If you also had radiotherapy to the chest, you may be offered earlier breast screening (for women) and heart checks.

Returning to normal life

Recovery is gradual. Energy often takes several months to return after the last cycle, and some people notice difficulties with concentration or memory for a while. Hair usually starts to grow back within a few weeks of finishing.

Building up activity step by step, eating well and keeping regular sleep habits can all help. Many people return to work, study and sport, and talking to others who have been through ABVD can be reassuring.

9. Alternatives

Alternative When it is considered
AVD (without bleomycin) After a clear PET scan, or in older people
Brentuximab vedotin with AVD Some advanced-stage disease
Escalated BEACOPP Younger people with advanced, high-risk disease
Immune checkpoint inhibitors Relapsed disease, and increasingly with chemotherapy in advanced disease
Autologous stem cell transplant Relapse after first treatment
Allogeneic stem cell transplant Selected people after several relapses

10. Frequently asked questions

Question Answer
Will I lose my hair? Usually some or all; it grows back after treatment
Can I work during ABVD? Many people work part-time; tiredness varies
Will I be able to have children? Most people’s fertility recovers, but discuss preservation beforehand
Why is my urine red? Doxorubicin colours urine for a day or two
Can I exercise? Gentle exercise is encouraged; avoid heavy exertion if counts are low
What if I miss a treatment? Your team will rearrange it; try to keep to the schedule where possible
Can I drink alcohol? Small amounts are usually fine; ask your team
Is ABVD given in hospital overnight? Usually not; it is a day treatment
Can I have vaccines? Inactivated vaccines such as the flu vaccine are usually advised; live vaccines are avoided
Do I need radiotherapy too? Sometimes, depending on stage and scan results

11. Questions to ask your care team

  • How many cycles of ABVD will I need?
  • When will I have a PET scan, and how will it change my treatment?
  • Will bleomycin be stopped after the scan?
  • Will I need radiotherapy?
  • How will you check my heart and lungs?
  • What should I do if I get a fever?
  • What fertility options are available?

Resources

  1. Canellos, G.P. et al. (1992) ‘Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD’, New England Journal of Medicine, 327(21), pp. 1478-1484.
  2. Connors, J.M. et al. (2018) ‘Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma’, New England Journal of Medicine, 378(4), pp. 331-344.
  3. Johnson, P. et al. (2016) ‘Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma’, New England Journal of Medicine, 374(25), pp. 2419-2429.
  4. Radford, J. et al. (2015) ‘Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma’, New England Journal of Medicine, 372(17), pp. 1598-1607.
  5. National Cancer Institute (2026) ABVD. Available at: https://www.cancer.gov/about-cancer/treatment/drugs/abvd (Accessed: October 2026).
  6. National Cancer Institute (2026) Hodgkin Lymphoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.